Posted on 14 January 2015
Vedanta Biosciences announced a license agreement with Janssen Biotech, for Vedanta's lead microbiome pharmaceutical candidate (VE202), which has demonstrated efficacy in published preclinical studies using models of autoimmune disease.
Under terms of the agreement, which was facilitated by the Johnson & Johnson Innovation Center in Boston, Janssen will develop and seek to commercialize the pharmaceutical candidate in inflammatory bowel disease (IBD).
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
Vedanta will receive an up-front payment and is eligible to receive development and commercialization milestone payments for an IBD indication up to a potential total of $241 million, plus possible additional consideration related to commercialization.
Vedanta may continue to explore other disease indications and Janssen and Vedanta may elect to develop and commercialize within one or more additional indications with terms similar to the IBD indication.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends